scholarly journals Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis

2007 ◽  
Vol 13 (6) ◽  
pp. 938-939 ◽  
Author(s):  
Takuya Hashimoto ◽  
Yasuhiko Sugawara ◽  
Masatoshi Makuuchi
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Human Leukocyte Antigen ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Human Leukocyte ◽  
Biliary Cirrhosis ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Leukocyte Antigen

Living donor liver transplantation for patients immunized against human leukocyte antigen

2012 ◽  
Vol 20 (3) ◽  
pp. 279-285 ◽  
Author(s):  
Junichi Shindoh ◽  
Yasuhiko Sugawara ◽  
Sumihito Tamura ◽  
Junichi Kaneko ◽  
Noriyo Yamashiki ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Human Leukocyte Antigen ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Human Leukocyte ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Leukocyte Antigen

scholarly journals Switching From Tacrolimus to Cyclosporine A to Prevent Primary Biliary Cirrhosis Recurrence After Living-Donor Liver Transplantation

10.9738/cc188 ◽  
2013 ◽  
Vol 98 (2) ◽  
pp. 156-159 ◽  
Author(s):  
Hiroaki Shiba ◽  
Shigeki Wakiyama ◽  
Yasuro Futagawa ◽  
Takeshi Gocho ◽  
Ryusuke Ito ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Primary Biliary Cirrhosis ◽  
Cyclosporine A ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Immunosuppressive Agents ◽  
Biliary Cirrhosis ◽  
Protective Effects ◽  
Donor Liver ◽  
Donor Liver Transplantation

Abstract Recurrence of primary biliary cirrhosis (PBC) after liver transplantation has been shown to negatively affect graft and patient survival. Recently, protective effects of cyclosporine A against PBC recurrence after liver transplantation have been reported. Participants were 4 patients who underwent living-donor liver transplantation (LDLT) for end-stage liver disease due to PBC. Tacrolimus was used for initial immunosuppression, and this was switched to cyclosporine A at least 3 months after liver transplantation. Targeted trough level of cyclosporine A was 20 times that of tacrolimus. We assessed liver and renal function, as well as antimitochondrial M2 antibody for recipients prior to LDLT, as well as before and after switching immunosuppressive agents. Patients were 1 man and 3 women, and they were ages 45 to 47 years at LDLT. Timing of switching from tacrolimus to cyclosporine A was 13, 3, 7, and 4 months respectively after liver transplantation, and all 4 patients have been on cyclosporine A without adverse effects at 20 to 46 months after transplantation. In 2 of 4 patients who had high titers of antimitochondrial M2 antibody before transplantation, antibody titer did not elevate after LDLT. In the other 2 patients without elevation of antimitochondrial M2 antibody, the titer did not turn positive. Switching from tacrolimus to cyclosporine A was possible without medical problems, and all patients exhibit no recurrence of PBC. Cyclosporine A may be useful for prevention of PBC recurrence after LDLT.

Sign in / Sign up

Export Citation Format

Share Document